LEADER 01648nam  2200445z- 450 
001 9910694589403321
005 20101017081016.0
035   $a(CKB)5860000000026321
035   $a(BIP)026939274
035   $a(EXLCZ)995860000000026321
100   $a20220406c2008uuuu  -u-         -
101 0 $aeng
200 10$aImpact of our antitrust laws on community pharmacies and their patients $ehearing before the Task Force on Antitrust and Competition Policy of the  Committee on the Judiciary, House of Representatives, One Hundred Tenth Congress, first session, October 18, 2007
215   $a1 online resource (iii, 132 p.) 
311   $a0-16-081300-X 
517   $aImpact of Our Antitrust Laws on Community Pharmacies and Their Patients
606   $aAntitrust law$zUnited States
606   $aDrugstores$xLaw and legislation$zUnited States
606   $aPharmacist and patient$zUnited States
606   $aHealth insurance$xLaw and legislation$zUnited States
606   $aWitnesses, FTC
610   $aAntitrust law
610   $aDrugstores
610   $aPatients
610   $aHealth insurance
610   $aWitnesses
610   $aLaw
610   $aBusiness & economics
610   $aMedical
615  0$aAntitrust law
615  0$aDrugstores$xLaw and legislation
615  0$aPharmacist and patient
615  0$aHealth insurance$xLaw and legislation
615  4$aWitnesses, FTC.
700   $aWales$b David$01351270
701   $aWales$b David$01351270
906   $aBOOK
912   $a9910694589403321
996   $aImpact of our antitrust laws on community pharmacies and their patients$93092183
997   $aUNINA